Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol 2013; 19(27): 4400-4408 [PMID: 23885153 DOI: 10.3748/wjg.v19.i27.4400]
Corresponding Author of This Article
Lu-Nan Yan, MD, PhD, Liver Transplantation Center, West China Hospital of Sichuan University, Wuhou District, Chengdu 610041, Sichuan Province, China. yanlunandoctor@163.com
Research Domain of This Article
Surgery
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 21, 2013; 19(27): 4400-4408 Published online Jul 21, 2013. doi: 10.3748/wjg.v19.i27.4400
Table 1 Downstaging treatments n (%)
LT group
LR group
Number of treatments
31
35
TACE only
15 (48.4)
18 (51.4)
One time
5
7
Two times
8
7
Three times
2
4
RAF only
7 (22.6)
10 (28.6)
One time
5
6
Two time
2
4
TACE + RAF
4 (12.9)
3 (8.6)
TACE + TACE + RAF
3 (9.7)
2 (5.7)
TACE + RAF + TACE
2 (6.5)
2 (5.7)
Table 2 Baseline demographic and tumor characteristics in the two groups
LT group (n = 31)
LR group (n = 35)
P value
Age (yr)
43.0 ± 8.2
45.5 ± 8.1
0.212
Gender (male:female)
20:11
20:15
0.544
Weight (kg)
68.6 ± 7.8
65.8 ± 10.6
0.241
Height (cm)
166.9 ± 8.6
164.6 ± 9.3
0.302
BMI (kg/m2)
22.8 ± 1.8
23.2 ± 2.4
0.404
Underlying liver disease
0.901
HBV
29
33
HCV
1
1
HBV and HCV
1
1
MELD score
8.6 ± 3.8
8.7 ± 4.7
0.866
Child score
0.617
A (5-6)
20
23
B (7-9)
11
12
C (≥ 10)
0
0
Serum creatinine (μmol/L)
71.3 ± 24.1
64.3 ± 20.9
0.212
Active lesion number (Pre-/Post-downstage)
0.672/0.721
One target
13/16
15/19
Two targets
10/9
14/11
Three targets
8/6
6/5
Total diameter of the tumors (cm)
6.8 ± 2.1/ 4.5 ± 1.7
6.7 ± 2.3/4.1 ± 1.9
0.786/0.376
AFP level (ng/mL)
Pre-downstage
1425.4 ± 1512.6
1332.9 ± 1122.5
0.777
Post-downstage
218.0 ± 244.0
248.6 ± 267.6
0.631
Tumor differentiation
0.960
Well
16
19
Moderate
7
6
Poor
8
10
Ishak score
4.6 ± 1.5
3.9 ± 1.3
0.069
Table 3 Complications after liver transplantation or liver resection
Complications
LT group (n = 31)
LR group (n = 35)
Bile leakage
2 (Grade I, I)
1 (Grade I)
Intra-abdominal bleeding
2 (Grade I, V)
2 (Grade II, III)
Wound infection
2 (Grade I, I)
1 (Grade I)
Pleural effusion
1 (Grade III)
2 (Grade I, II)
Respiratory failure
2 (Grade IV, V)
1 (Grade V)
Ileus
1 (Grade II)
0
Hepatic artery thrombosis
1 (Grade II)
0
Subphrenic abscess
1 (Grade III)
1 (Grade III)
Liver failure
1 (Grade V)
0
Rejection
2 (Grade II, V)
0
Table 4 Risk factors for tumor recurrence in the two groups
Factors
Odds
95%CI
P value
Tumor differentiation
2.225
1.365-3.882
0.041
Post-downstaging AFP level > 400 ng/mL
2.113
1.971-3.104
0.015
Citation: Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol 2013; 19(27): 4400-4408